UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

European journal of clinical pharmacology, 2011-05, Vol.67 (5), p.483-492

2011

Link zum Volltext

Verfügbarkeit prüfen

Disposition of 14C-eptifibatide after intravenous administration to healthy men

Clinical therapeutics, 1998-03, Vol.20 (2), p.307-323

1998

Link zum Volltext

Verfügbarkeit prüfen

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

Current medical research and opinion, 2005-08, Vol.21 (8), p.1171-1179

2005

Link zum Volltext

Verfügbarkeit prüfen

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

Current medical research and opinion, 2004-06, Vol.20 (6), p.955-965

2004

Link zum Volltext

Verfügbarkeit prüfen

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

Clinical pharmacology and therapeutics, 1991-08, Vol.50 (1), p.181-191

1991

Link zum Volltext

Verfügbarkeit prüfen

Endopeptidase 24.11 Inhibition by SCH 42495 in Essential Hypertension

Hypertension (Dallas, Tex. 1979), 1993-07, Vol.22 (1), p.119-126

1993

Link zum Volltext

Verfügbarkeit prüfen

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI

Chest, 2012-10, Vol.142 (4), p.685A-685B

2012

Link zum Volltext

Verfügbarkeit prüfen

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

Chest, 2013-12, Vol.144 (6), p.1795-1802

2013

Link zum Volltext

Verfügbarkeit prüfen

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

Chest, 2000-12, Vol.118 (6), p.1538-1546

2000

Link zum Volltext

Verfügbarkeit prüfen

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.291-300

2012

Link zum Volltext

Verfügbarkeit prüfen

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Chest, 2007-10, Vol.132 (4), p.479A-479A

2007

Link zum Volltext

Verfügbarkeit prüfen

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Chest, 2010-01, Vol.137 (1), p.115-121

2010

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Current medical research and opinion, 2004-08, Vol.20 (8), p.1197

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic interaction between ezetimibe and rosuvastatin

Current medical research and opinion, 2004-08, Vol.20 (8), p.1185-1195

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Circulation (New York, N.Y.), 2001-07, Vol.104 (4), p.406-411

2001

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.249-258

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

Current medical research and opinion, 2004-09, Vol.20 (9), p.1493-1500

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European journal of clinical pharmacology, 2012-07, Vol.68 (7), p.1049-1056

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Clinical therapeutics, 1995-03, Vol.17 (2), p.241-251

1995

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Clinical therapeutics, 1997-09, Vol.19 (5), p.1002-1012

1997

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1501-1508

2012

Link zum Volltext

Verfügbarkeit prüfen

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Clinical therapeutics, 2001-06, Vol.23 (6), p.871-885

2001

Link zum Volltext

Verfügbarkeit prüfen

Trimethoprim alters the disposition of procainamide and N‐acetylprocainamide

Clinical pharmacology and therapeutics, 1988-10, Vol.44 (4), p.467-477

1988

Link zum Volltext

Verfügbarkeit prüfen

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1509-1516

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Male
(22)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Adult
(19)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Pharmacology. Drug Treatments
(15)
Female
(14)
Middle Aged
(13)
Pharmacokinetics
(13)
Pharmacology & Pharmacy
(11)
Pharmacodynamics
(8)
Adolescent
(7)
Azetidines - Pharmacokinetics
(7)
Drug Interactions
(7)
Ezetimibe
(7)
General & Internal Medicine
(7)
Pharmacology
(7)
Anticholesteremic Agents - Pharmacokinetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

European Journal Of Clinical Pharmacology
(6)
Chest
(5)
Current Medical Research And Opinion
(5)
Clinical Therapeutics
(4)
Clinical Pharmacology And Therapeutics
(2)
Circulation
(1)
Hypertension
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

Disposition of 14C-eptifibatide after intravenous administration to healthy men

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

Endopeptidase 24.11 Inhibition by SCH 42495 in Essential Hypertension

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Pharmacodynamic interaction between ezetimibe and rosuvastatin

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Trimethoprim alters the disposition of procainamide and N‐acetylprocainamide

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

Aktive Filter

Suchergebnisse filtern